434 related articles for article (PubMed ID: 26220066)
21. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death.
Apple FS; Murakami MM; Pearce LA; Herzog CA
Clin Chem; 2004 Dec; 50(12):2279-85. PubMed ID: 15364888
[TBL] [Abstract][Full Text] [Related]
22. No Added Value of Novel Biomarkers in the Diagnostic Assessment of Patients Suspected of Acute Coronary Syndrome.
Poldervaart JM; Röttger E; Dekker MS; Zuithoff NP; Verheggen PW; de Vrey EA; Wildbergh TX; van 't Hof AW; Mosterd A; Hoes AW
PLoS One; 2015; 10(7):e0132000. PubMed ID: 26177390
[TBL] [Abstract][Full Text] [Related]
23. Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure.
Jungbauer CG; Riedlinger J; Block D; Stadler S; Birner C; Buesing M; König W; Riegger G; Maier L; Luchner A
Biomark Med; 2014; 8(6):777-89. PubMed ID: 25224934
[TBL] [Abstract][Full Text] [Related]
24. Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients.
Cho H; Lee S; Sim SH; Park IH; Lee KS; Kwak MH; Kim HJ
Breast Cancer Res Treat; 2020 Jul; 182(2):333-343. PubMed ID: 32468335
[TBL] [Abstract][Full Text] [Related]
25. [The role of biochemical markers with special regard to troponin, CK-MB, NT-proBNP as early biomarkers of cardiotoxicity among women after chemotherapy due to breast cancer].
Stachowiak P; Milchert-Leszczyńska M; Falco M; Polakowska M; Wojtarowicz A; Kaliszczak R; Safranow K; Kornacewicz-Jach Z
Przegl Lek; 2016; 73(6):359-63. PubMed ID: 29668198
[TBL] [Abstract][Full Text] [Related]
26. Identification of Clinical and Laboratory Variables Associated with Cardiotoxicity Events Due to Doxorubicin in Breast Cancer Patients: A 1-Year Follow-Up Study.
Simões R; Silva LM; de Oliveira AN; Alves MT; Pestana RMC; de Souza IDP; Oliveira HHM; Soares CE; Sabino AP; Gomes KB
Cardiovasc Toxicol; 2021 Feb; 21(2):106-114. PubMed ID: 32844368
[TBL] [Abstract][Full Text] [Related]
27. [Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab].
Pistillucci G; Ciorra AA; Sciacca V; Raponi M; Rossi R; Veltri E
Clin Ter; 2015; 166(1):e67-71. PubMed ID: 25756270
[TBL] [Abstract][Full Text] [Related]
28. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Ponde N; Bradbury I; Lambertini M; Ewer M; Campbell C; Ameels H; Zardavas D; Di Cosimo S; Baselga J; Huober J; Izquierdo M; Fumagalli D; Bozovic-Spasojevic I; Maetens M; Harbeck N; Pusztai L; Berghorn M; Im YH; Borrego MR; Chen DR; Rodeheffer R; Piccart M; Suter T; de Azambuja E
Breast Cancer Res Treat; 2018 Apr; 168(3):631-638. PubMed ID: 29280043
[TBL] [Abstract][Full Text] [Related]
29. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
[TBL] [Abstract][Full Text] [Related]
30. N-terminal pro B-type natriuretic peptide and angiogenic biomarkers in the prognosis of adverse outcomes in women with suspected preeclampsia.
Álvarez-Fernández I; Prieto B; Rodríguez V; Ruano Y; Escudero AI; Álvarez FV
Clin Chim Acta; 2016 Dec; 463():150-157. PubMed ID: 27983995
[TBL] [Abstract][Full Text] [Related]
31. Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy.
El-Sherbeny WS; Sabry NM; Sharbay RM
J Echocardiogr; 2019 Jun; 17(2):76-83. PubMed ID: 30099714
[TBL] [Abstract][Full Text] [Related]
32. High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy.
Advani P; Hoyne J; Moreno-Aspita A; Dubin M; Brock S; Harlow C; Chumsri S; Suter T; Blackshear JL
Chemotherapy; 2017; 62(6):334-338. PubMed ID: 28704807
[TBL] [Abstract][Full Text] [Related]
33. Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab.
Andersson AE; Linderholm B; Giglio D
Acta Oncol; 2021 Apr; 60(4):475-481. PubMed ID: 33191817
[TBL] [Abstract][Full Text] [Related]
34. Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer.
Goel S; Simes RJ; Beith JM
Asia Pac J Clin Oncol; 2011 Sep; 7(3):276-80. PubMed ID: 21884439
[TBL] [Abstract][Full Text] [Related]
35. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction.
Narayan HK; French B; Khan AM; Plappert T; Hyman D; Bajulaiye A; Domchek S; DeMichele A; Clark A; Matro J; Bradbury A; Fox K; Carver JR; Ky B
JACC Cardiovasc Imaging; 2016 Oct; 9(10):1131-1141. PubMed ID: 27085442
[TBL] [Abstract][Full Text] [Related]
36. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis.
Michel L; Mincu RI; Mahabadi AA; Settelmeier S; Al-Rashid F; Rassaf T; Totzeck M
Eur J Heart Fail; 2020 Feb; 22(2):350-361. PubMed ID: 31721381
[TBL] [Abstract][Full Text] [Related]
37. Robust predictive markers are needed for early detection of trastuzumab-related cardiac dysfunction in breast cancer.
Altundag K
Breast Cancer; 2017 Nov; 24(6):794. PubMed ID: 28275991
[No Abstract] [Full Text] [Related]
38. Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors.
Serrano JM; Mata R; González I; Del Castillo S; Muñiz J; Morales LJ; Espinosa MJ; Moreno F; Jiménez R; Cristobal C; Graupner C; Talavera P; Landaluce CG; Curcio A; Alonso J; Guerra JA; Alonso JJ
Int J Cardiol; 2023 Jul; 382():52-59. PubMed ID: 37080467
[TBL] [Abstract][Full Text] [Related]
39. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
[TBL] [Abstract][Full Text] [Related]
40. Protective effects of acute exercise prior to doxorubicin on cardiac function of breast cancer patients: A proof-of-concept RCT.
Kirkham AA; Shave RE; Bland KA; Bovard JM; Eves ND; Gelmon KA; McKenzie DC; Virani SA; Stöhr EJ; Warburton DER; Campbell KL
Int J Cardiol; 2017 Oct; 245():263-270. PubMed ID: 28735755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
